Investigating how certain immune cells affect cancer and autoimmune diseases
Official title: Testing the contribution of ex-Tregs to autoimmunity and cancer immunity
Funded at University of California Berkeley · NIH-11119796 · Data updated 2026-11-12
This study is looking at a special type of immune cell called ex-Tregs to see how they can help fight cancer or possibly cause autoimmune diseases when other immune cells are removed, which could help us find better ways to treat these conditions.
Quick facts
| Grant type | R21 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of California Berkeley NIH-funded |
| Lab location | 1 site (Berkeley, United States) |
| Project start | June 12, 2025 |
| Project end | May 31, 2027 |
| Funding year | 2025 |
| Award (this year) | $441,202 |
| NIH project number | 1R21AI191077-01 |
| Project ID | NIH-11119796 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research include individuals diagnosed with autoimmune diseases or cancer who are seeking innovative treatment options.
✕Less likely to help
Patients with stable autoimmune conditions or those not currently undergoing treatment for cancer may not benefit from this research.
What this research studies
This research explores the role of ex-Tregs, a type of immune cell that can influence both cancer immunity and autoimmune diseases. By examining how these cells behave when regulatory T cells (Tregs) are depleted, the study aims to understand their potential to promote immune responses against tumors or trigger autoimmune conditions. The researchers will use advanced genetic models to track these immune cells and assess their impact on disease progression. This could lead to new insights into how to better manage cancer and autoimmune disorders.
Why it matters
Potential benefit: If successful, this research could lead to improved treatments for patients with cancer and autoimmune diseases by harnessing the immune system more effectively.
How similar studies have gone: Previous research has shown promising results in understanding immune regulation, but the specific role of ex-Tregs in this context is still being explored, making this a novel investigation.
Where this research is happening
-
University of California Berkeley
Berkeley, United States Active
Researchers
- Principal investigator: Dupage, Michel — University of California Berkeley
- Study coordinator: Dupage, Michel
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.